Kidney Disease

Empagliflozin Reduced Risk of Renal Disease Progression, CV Death Across CKD Spectrum in EMPA-KIDNEY
November 07, 2022

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

Exercise Training Program Found to Improve Cardiorespiratory Fitness in Older Adults with Advanced CKD
August 09, 2022

In a study of nearly 100 adults with CKD stages G3b-4 and medical comorbidity, a 12-month exercise program was found safe and improved physical functioning.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes
July 22, 2022

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
May 18, 2022

Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.

ADA 2021: Baseline Insulin Use May not Impact Benefits of Finerenone in Patients with CKD, T2D
June 29, 2021

ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.

ADA 2021: Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD
June 29, 2021

ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.

FDA Approves Dapagliflozin to Treat Chronic Kidney Disease in Adults at Risk of Progression, Regardless of Diabetes Status
May 03, 2021

Dapagliflozin is the first SGLT-2 inhibitor to receive FDA approval for the treatment of CKD, regardless of diabetes status.

SGLT2 Inhibitors Enter Vast Treatment Void for High-risk CKD Patients
December 08, 2020

Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.

DAPA-CKD Investigator: "PCPs Should be First-line Prescribers of SGLT2 Inhibitors"
December 03, 2020

Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.

Professor John McMurray Highlights DAPA-CKD Trial Outcomes
December 02, 2020

DAPA-CKD investigator Professor John McMurray details the trial and renal and cardiovascular outcomes for Patient Care Online.